OTCMKTS:MEDXF Medexus Pharmaceuticals (MEDXF) Stock Price, News & Analysis $1.98 -0.08 (-3.98%) As of 02:42 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartShort InterestBuy This Stock About Medexus Pharmaceuticals Stock (OTCMKTS:MEDXF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get MEDXF alerts:Sign Up Key Stats Today's Range$1.97▼$2.0850-Day Range$1.85▼$2.2952-Week Range$1.27▼$3.88Volume9,281 shsAverage Volume20,069 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingStrong Buy Company Overview Medexus Pharmaceuticals, Inc. is a specialty pharmaceutical company headquartered in Mississauga, Ontario. The company focuses on acquiring, developing and commercializing niche prescription drug products for markets in Canada and the United States. Its efforts are aimed at underserved therapeutic areas, including rare diseases, oncology, hematology and dermatology. Through strategic licensing and partnership agreements with international pharmaceutical firms, Medexus sources late‐stage and marketed assets, then manages their regulatory approval and commercialization. The company’s portfolio includes treatments for disorders such as immune thrombocytopenia, neutropenia and other hematologic conditions, as well as therapies for certain solid tumors and skin diseases. Its business model emphasizes efficient product launches and market penetration by leveraging established distribution channels and clinical expertise. Founded in 2015, Medexus has built a commercially focused infrastructure encompassing regulatory affairs, medical affairs, sales and marketing, and market access. While primarily serving Canadian patients and healthcare providers, the company has selectively expanded into the U.S. specialty market via targeted launch strategies. Medexus’ leadership team draws on decades of experience in pharmaceutical development and commercialization to guide its growth trajectory.AI Generated. May Contain Errors. Read More Receive MEDXF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medexus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MEDXF Stock News HeadlinesMedexus Pharmaceuticals Inc. (TSE:MDP) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?September 25, 2025 | finance.yahoo.comMedexus Pharmaceuticals Inc.: Medexus Announces Strong Fiscal Year 2025 Results, Including Initial Results from Launch of GRAFAPEX (treosulfan) for ... - FinanzNachrichten.deJune 26, 2025 | finanznachrichten.deArizona-made nanochips the new millionaire maker?George Gilder handed President Reagan the first microchip that helped create $6.5 trillion in wealth over the last 40 years. Now he's stepping forward with an even bigger prediction about what's being built in the Arizona desert. He believes 3 little-known companies will explode when a bombshell announcement just days from now. Smart investors are already positioning themselves.October 6 at 2:00 AM | Banyan Hill Publishing (Ad)Medexus Pharmaceuticals Inc. (MEDXF) Q4 2025 Earnings Call TranscriptJune 26, 2025 | seekingalpha.comRAYMOND JAMES LTD. Upgrades Medexus Pharmaceuticals (MEDXF)April 8, 2025 | msn.comRaymond James Reaffirms Their Buy Rating on Medexus Pharmaceuticals Inc (MDP)February 7, 2025 | markets.businessinsider.comMedexus Pharmaceuticals, Inc. (MEDXF) Q3 2025 Earnings Call TranscriptFebruary 6, 2025 | seekingalpha.comMedexus Pharmaceuticals Announces Pricing of $30 Million Overnight Marketed Public Offering of Common SharesJanuary 28, 2025 | globenewswire.comSee More Headlines MEDXF Stock Analysis - Frequently Asked Questions How have MEDXF shares performed this year? Medexus Pharmaceuticals' stock was trading at $2.4150 at the start of the year. Since then, MEDXF shares have decreased by 18.1% and is now trading at $1.9780. How do I buy shares of Medexus Pharmaceuticals? Shares of MEDXF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolOTCMKTS:MEDXF CIKN/A Webwww.medexus.com Phone(514) 344-8765FaxN/AEmployees98Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (OTCMKTS:MEDXF) was last updated on 10/6/2025 by MarketBeat.com Staff From Our Partners$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredElon’s Out 🚫. Trump’s DOGE Payouts Keep Flowing (Up to $32K a Year)DOGE payouts are already moving. Every 90 days, billions flow out — whether you’ve claimed your share or not. ...Angel Publishing | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredGet my No. 1 gold stock nowGold recently broke past $3,800 per ounce – setting yet another new all-time high. And Wall Street banks sa...Stansberry Research | SponsoredThe $20 stock that could make silicon chips obsolete$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medexus Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Medexus Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.